cme
The Diagnosis and Treatment of Giant Cell Arteritis
Dtsch Arztebl Int 2013; 110(21): 376-86. DOI: 10.3238/arztebl.2013.0376
; ; ;
| 1. | Horton BT, Magath TB, Brown GE: An undescribed form of arteritis of the temporal vessels. Proc Mayo Clin 1932; 7: 700–1. |
| 2. | Jennette JC, Falk RJ, Andrassy K, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187–92. CrossRef MEDLINE |
| 3. | Vaith P, Warnatz K: Clinical and serological findings of giant-cell arteritis. Z Rheumatol 2009; 68: 124–31. CrossRef MEDLINE |
| 4. | Blockmans D: The use of (18F)fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol 2009; 21: 15–22. MEDLINE |
| 5. | Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL: Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3532–7. CrossRef MEDLINE |
| 6. | Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3522–31. CrossRef MEDLINE |
| 7. | Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL: Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2012 Dec 19. [Epub ahead of print]. CrossRef MEDLINE |
| 8. | Vaith P, Bley T: Primär systemische Vaskulitiden – große Gefäße. In: Peter HH, Pichler WJ, Müleer-Ladner (eds): Klinische Immunologie. 3rd edition. München: Urban & Fischer 2012; 363–9. |
| 9. | Salvarani C, Cantini F, Boiardi L, Hunder GG: Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261–71. CrossRef MEDLINE |
| 10. | Dasgupta B, Cimmino MA, Maradit-Kremers H, et al.: 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484–92. CrossRef MEDLINE PubMed Central |
| 11. | Ness T, Auw-Hadrich C, Schmidt D: Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment. Ophthalmologe 2006; 103: 296–301. MEDLINE |
| 12. | Kale N, Eggenberger E: Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol 2010; 21: 417–22. CrossRef MEDLINE |
| 13. | Kermani TA, Schmidt J, Crowson CS, et al.: Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41: 866–71. CrossRef MEDLINE |
| 14. | Hunder GG, Bloch DA, Michel BA, et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–8. CrossRef MEDLINE |
| 15. | Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al.: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005; 84: 277–90. CrossRef MEDLINE |
| 16. | Ciccarelli M, Jeanmonod D, Jeanmonod R: Giant cell temporal arteritis with a normal erythrocyte sedimentation rate: report of a case. Am J Emerg Med 2009; 27: 255: e1–3. MEDLINE |
| 17. | Parikh M, Miller NR, Lee AG, et al.: Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113: 1842–5. CrossRef MEDLINE |
| 18. | Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336–42. CrossRef MEDLINE |
| 19. | Bley TA, Uhl M, Carew J, et al.: Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 2007; 28: 1722–7. CrossRef MEDLINE |
| 20. | Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M: High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005; 184: 283–7. CrossRef MEDLINE |
| 21. | Bley TA, Wieben O, Vaith P, Schmidt D, Ghanem NA, Langer M: Magnetic resonance imaging depicts mural inflammation of the temporal artery in giant cell arteritis. Arthritis Rheum 2004; 51: 1062–1063; author reply 1064. CrossRef MEDLINE |
| 22. | Hauenstein C, Reinhard M, Geiger J, et al.: Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology 2012; 51: 1999–03. CrossRef MEDLINE |
| 23. | Poller DN, van Wyk Q, Jeffrey MJ: The importance of skip lesions in temporal arteritis. J Clin Pathol 2000; 53: 137–9. CrossRef MEDLINE PubMed Central |
| 24. | Zhou L, Luneau K, Weyand CM, Biousse V, Newman NJ, Grossniklaus HE: Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology 2009; 116: 1574–80. CrossRef MEDLINE PubMed Central |
| 25. | Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K: Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 2010; 49: 1158–63. CrossRef MEDLINE |
| 26. | Kermani TA, Schafer VS, Crowson CS, et al.: Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res 2010; 62: 149–54. MEDLINE |
| 27. | Mukhtyar C, Guillevin L, Cid MC: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318–23. CrossRef MEDLINE |
| 28. | Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703–8. CrossRef MEDLINE |
| 29. | Mazlumzadeh M, Hunder GG, Easley KA, et al.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310–8. CrossRef MEDLINE |
| 30. | Chevalet P, Barrier JH, Pottier P, et al.: A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000; 27: 1484–91. MEDLINE |
| 31. | Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204–15. CrossRef MEDLINE |
| 32. | Wipfler-Freissmuth E, Loock J, Moosig F, Dejaco C, Duftner C, Schirmer M: Current therapeutic options for giant cell arteritis. Z Rheumatol 2009; 68: 132–6. MEDLINE |
| 33. | Mahr AD, Jover JA, Spiera RF, et al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789–97. CrossRef MEDLINE |
| 34. | De Silva M, Hazleman BL: Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136–8. CrossRef MEDLINE PubMed Central |
| 35. | Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621–30. CrossRef MEDLINE |
| 36. | Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625–30. CrossRef MEDLINE |
| 37. | Lee MS, Smith SD, Galor A, Hoffman GS: Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306–9. CrossRef MEDLINE |
| 38. | Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332–7. CrossRef MEDLINE |
| 39. | Ness T, Schmidt D: Arteriitis temporalis: Temporalarterienbiopsie, Anamnese und Blutwerte. Zeitschrift für praktische Augenheilkunde 2005; 26: 327–32. |
| 40. | Dasgupta B, Borg FA, Hassan N, et al.: BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010; 49: 1594–7. CrossRef MEDLINE |
| e1. | Boesen P, Sorensen SF: Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982–1985. Arthritis Rheum 1987; 30: 294–9. MEDLINE |
| e2. | Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al.: Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine 2007; 86: 61–8. MEDLINE |
| e3. | Gran JT, Myklebust G: The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. J Rheumatol 1997; 24: 1739–43. MEDLINE |
| e4. | Noltorp S, Svensson B: High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 351–5. MEDLINE |
| e5. | Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL: Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53: 93–9. CrossRef MEDLINE |
| e6. | Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG: The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192–4. CrossRef MEDLINE |
| e7. | Wagner AD: Giant cell arteritis (temporal arteritis). Pathophysiology, immunology. Ophthalmologe 2006; 103: 302–7. MEDLINE |
| e8. | Salvarani C, Cantini F, Hunder GG: Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234–45. CrossRef MEDLINE |
| e9. | Schmidt J, Warrington KJ: Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging 2011; 28: 651–66. CrossRef MEDLINE |
| e10. | Chew SS, Kerr NM, Danesh-Meyer HV: Giant cell arteritis. J Clin Neurosci 2009; 16: 1263–8. CrossRef MEDLINE |
| e11. | Evans JM, O’Fallon WM, Hunder GG: Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122: 502–7. CrossRef MEDLINE |
| e12. | Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine 2009; 88: 221–6. MEDLINE |
| e13. | Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 2000; 79: 283–92. MEDLINE |
| e14. | Hayreh SS, Podhajsky PA, Zimmerman B: Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509–20. CrossRef MEDLINE |
| e15. | Ness T, Schmidt D: Arteriitis temporalis: Temporalarterienbiopsie, Anamnese und Blutwerte. Zeitschrift für praktische Augenheilkunde 2005; 26: 327–32. |
| e16. | Rahman W, Rahman FZ: Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 2005; 50: 415–28. CrossRef MEDLINE |
| e17. | Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG: Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100: 550–5. MEDLINE |
| e18. | Jonasson F, Cullen JF, Elton RA: Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 1979; 24: 111–7. MEDLINE |
| e19. | Hayreh SS: Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye 2004; 18: 1188–206. CrossRef MEDLINE |
| e20. | Schmidt D: Ocular ichemia syndrome—a malignant course of giant cell arteritis. Eur J Med Res 2005; 10: 233–42. MEDLINE |
| e21. | Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al.: Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497–504. CrossRef MEDLINE |
| e22. | Hayreh SS, Podhajsky PA, Zimmerman B: Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998; 125: 521–6. CrossRef MEDLINE |
| e23. | Schmidt WA, Gromnica-Ihle E: What is the best approach to diagnosing large-vessel vasculitis? Best Pract Res Clin Rheumatol 2005; 19: 223–42. CrossRef MEDLINE |
| e24. | Salvarani C, Cantini F, Boiardi L, Hunder GG: Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 2003; 21: 23–8. MEDLINE |
| e25. | Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ: Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041–8. CrossRef MEDLINE |
| e26. | Markl M, Uhl M, Wieben O, et al.: High resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 2006; 24: 423–7. CrossRef MEDLINE |
| e27. | Bley TA, Markl M, Schelp M, et al.: Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 2008; 47: 65–7. CrossRef MEDLINE |
| e28. | Hayreh SS, Podhajsky PA, Raman R, Zimmerman B: Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285–96. MEDLINE |
| e29. | Bhatti MT, Tabandeh H: Giant cell arteritis: diagnosis and management. Curr Opin Ophthalmol 2001; 12: 393–9. CrossRef MEDLINE |
| e30. | Weyand CM, Bartley GB: Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 1997; 123: 392–5. MEDLINE |
| e31. | Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987–92. CrossRef MEDLINE |
| e32. | Andersson R, Malmvall BE, Bengtsson BA: Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220: 465–9. CrossRef MEDLINE |
| e33. | Salvarani C, Macchioni PL, Tartoni PL, et al.: Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205–15. MEDLINE |
| e34. | Vaith P, Bley T: Primär systemische Vaskulitiden – große Gefäße. In: Peter HH, Pichler WJ, Müller-Ladner (eds): Klinische Immunologie. 3rd edition München: Urban & Fischer 2012; 363–9. |
| e35. | Nesher G, Rubinow A, Sonnenblick M: Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol 1997; 15: 303–6. MEDLINE |
| e36. | Nesher G, Sonnenblick M, Friedlander Y: Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283–6. MEDLINE |
| e37. | Gardiner PV, Griffiths ID: Sudden death after treatment with pulsed methylprednisolone. BMJ 1990; 300: 125. CrossRef MEDLINE PubMed Central |
| e38. | Saag KG, Emkey R, Schnitzer TJ, Brown JP, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–9. CrossRef MEDLINE |
